HBC Stock Overview
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hofseth BioCare ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.20 |
| 52 Week High | kr3.95 |
| 52 Week Low | kr1.90 |
| Beta | 0.43 |
| 1 Month Change | -1.35% |
| 3 Month Change | -15.06% |
| 1 Year Change | -34.33% |
| 3 Year Change | -73.87% |
| 5 Year Change | -22.81% |
| Change since IPO | -56.00% |
Recent News & Updates
Recent updates
Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt
Apr 01
We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt
Dec 22Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?
Apr 28Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt
Oct 16Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?
Feb 24How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?
Jan 28Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?
Dec 25
Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain
Nov 20Shareholder Returns
| HBC | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 3.8% | -1.9% | -1.7% |
| 1Y | -34.3% | -77.0% | 1.8% |
Return vs Industry: HBC exceeded the Norwegian Biotechs industry which returned -77% over the past year.
Return vs Market: HBC underperformed the Norwegian Market which returned 1.8% over the past year.
Price Volatility
| HBC volatility | |
|---|---|
| HBC Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: HBC has not had significant price volatility in the past 3 months.
Volatility Over Time: HBC's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 70 | Jon Odegard | www.hofsethbiocare.com |
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company’s products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. Hofseth BioCare ASA was incorporated in 2000 and is headquartered in Ålesund, Norway.
Hofseth BioCare ASA Fundamentals Summary
| HBC fundamental statistics | |
|---|---|
| Market cap | kr869.18m |
| Earnings (TTM) | -kr106.68m |
| Revenue (TTM) | kr218.51m |
4.0x
P/S Ratio-8.1x
P/E RatioIs HBC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBC income statement (TTM) | |
|---|---|
| Revenue | kr218.51m |
| Cost of Revenue | kr165.00m |
| Gross Profit | kr53.51m |
| Other Expenses | kr160.20m |
| Earnings | -kr106.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 24.49% |
| Net Profit Margin | -48.82% |
| Debt/Equity Ratio | 420.9% |
How did HBC perform over the long term?
See historical performance and comparison